menu

Improving Patient Outcomes: What Are the Beneficial and Potentially Clinically Relevant Adverse Effect Profiles of Antipsychotic

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Schizophrenia: A Promising Treatment Era Dawns

Improving Patient Outcomes: What Are the Beneficial and Potentially Clinically Relevant Adverse Effect Profiles of Antipsychotic Agents for SCZ?

MinuteCE®
ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
1.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
Documents
Comments
  • Overview

    Schizophrenia (SCZ) is a severely disabling psychiatric disorder that significantly impacts patients' social functions, work performance, and overall quality of life (QoL). Although current antipsychotics demonstrate efficacy in treating the positive symptoms of SCZ, they do not effectively treat the negative or cognitive symptom domains. They are associated with substantial adverse effects that lead to non-adherence and discontinuation. Recent studies have shown that 20% to 33% of patients do not respond adequately to conventional SCZ therapies, resulting in residual psychotic symptoms, poor functional status, and a dramatically reduced QoL. For decades, the treatment options for SCZ have all been centered around dopamine receptor antagonism. Emerging therapies that target TAAR1, muscarinic M1/M4, and serotonin 5-HT2A receptors are changing this treatment paradigm. This educational series explores the impact that SCZ has on individuals and their caretakers, how research into new therapies is moving away from blockading D2 receptors toward novel treatment targets related to TAAR1, muscarinic M1/M4, and serotonin 5-HT2A receptors, and the clinical implications of managing positive, negative, and cognitive symptoms associated with SCZ.

  • Target Audience

    This activity has been designed to meet the educational needs of the interprofessional team, including psychiatrists, nurse practitioners (NPs) and physician assistants (PAs) who specialize in psychiatry, as well as other clinicians involved in the management of patients with schizophrenia (SCZ).

  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    • Explain how the limitations associated with conventional treatments for SCZ have resulted in excessive burdens for patients and their caregivers, which contribute to poor outcomes
    • Outline the safety and efficacy profiles, limitations, and barriers associated with using conventional dopamine-centric antipsychotics approved for the treatment of SCZ
    • Describe the latest advances in SCZ research related to the cellular and molecular pathways underlying SCZ
    • Differentiate between emerging TAAR1 agonists versus muscarinic and serotonergic-based therapies in terms of the pharmacodynamics as well as efficacy and safety data from clinical trials
  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
     
    This activity was planned by and for the healthcare team, and learners will receive 1.50 Interprofessional Continuing Education (IPCE) credits for learning and change.

  • Faculty Disclosure of Commercial Relationships

    Disclosure Policy
    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs. 

    The following faculty have disclosed:

    Christoph U Correll, MD, chair for this educational event, receives a research grant and manages the fund for Janssen and Takeda; receives ownership interest from Cardio Diagnostics, Mindpax, LB Pharm, and Quantic; receives royalties from UpToDate; and receives consulting fees from AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Denovo, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Newron, Noven, Novo Nordisk, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma, Supernus, Takeda, Teva, and Viatris. 

    Jonathan Meyer, MD, faculty for this educational event, receives consulting fees for Alkermes, Axsome, Bioexcel, Cerevel, ITCI, Karuna, Neurocrine, Nove, Otsuka America, Inc., Relmada, Sunovion, and Teva. 

    Leslie Citrome, MD, MPH, faculty for this educational event, receives ownership interest (in the form of a small number of shares of common stock) from the following: Bristol-Myers Squibb, Eli Lilly, J & J, Merck, Pfizer purchased > 10 years ago; receives stock options from Reviva; receives royalties from Taylor & Francis (Editor-in-Chief, Current Medical Research and Opinion, 2022-present), Wiley (Editor-in-Chief, International Journal of Clinical Practice, through end of 2019), UpToDate (reviewer), Springer Healthcare (book), Elsevier (Topic Editor, Psychiatry, Clinical Therapeutics); receives consulting fees from AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Cerevel, Clinilabs, COMPASS, Eisai, Enteris BioPharma, HLS Therapeutics, Idorsia, INmune Bio, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Lyndra, Medavante-ProPhase, Marvin, Merck, Mitsubishi-Tanabe Pharma, Neurocrine, Neurelis, Novartis, Noven, Otsuka, Ovid, Praxis, Recordati, Relmada, Reviva, Sage, Sunovion, Supernus, Teva, University of Arizona, Vanda, and one-off ad hoc consulting for individuals/entities conducting marketing, commercial, or scientific scoping research; is a speaker for AbbVie/Allergan, Acadia, Alkermes, Angelini, Axsome, BioXcel, Eisai, Idorsia, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Recordati, Sage, Sunovion, Takeda, Teva, and CME activities organized by medical education companies such as Medscape, NACCME, NEI, Vindico, and Universities and Professional Organizations/Societies.   

  • Planners and Managers Disclosure List

    The following planners/reviewers/managers have disclosed:

    Canan Schumann, PharmD/PhD, planner for this educational event, has no relevant financial relationships with ineligible companies.

    William Mencia, MD, FACEHP, CHCP, reviewer for this educational event, has no relevant financial relationships with ineligible companies.

    TotalCME, Inc. planners and managers have no relevant commercial relationships to disclose.

    All the relevant financial relationships for these individuals have been mitigated.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Global Learning Collaborative (GLC) and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to view a site outside of MedEd On The Go, you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Acknowledgment

    This activity is supported by independent educational grants from Karuna Therapeutics, Sunovion and Otsuka. 

    This activity has been jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.

  • Fee Statement

    This activity is FREE to all participants.

  • Instructions for Completion

    During the period 4/24/2023 through 4/24/2024, registered participants wishing to receive continuing education credit for this activity must follow these steps:

    1. Read the learning objectives and faculty disclosures.
    2. Answer a pre-program question.
    3. View the program.
    4. Complete the post-test with a score of 100%. 
    5. Complete activity evaluation.
    6. Apply for credit and either bank your credits or print your certificate.

    For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule3 Oct 2023